EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Assessing non‐adjunctive CGM safety at home and in new markets (ANSHIN)

Christy Chao, Sarah B Andrade iD, Simon Bergford, Peter Calhoun, John B Welsh, Tomas C Walker, ANSHIN Study Group

Endocrinology, Diabetes & Metabolism · 2023

DOI: 10.1002/edm2.414 ↗

At a glance

Randomisierte kontrollierte Studie in Endocrinology, Diabetes & Metabolism, 2023. Written by Christy Chao and 6 co-authors. Institution: Dexcom, Inc., San Diego, California, USA. Major MEDLINE topics: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Ketoacidosis. Cited 3 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Continuous glucose monitoring (CGM) can guide treatment for people with type 1 (T1D) and type 2 diabetes (T2D). The ANSHIN study assessed the impact of non‐adjunctive CGM use in adults with diabetes using intensive insulin therapy (IIT). Materials and Methods This single‐arm, prospective, interventional study enrolled adults with T1D or T2D who had not used CGM in the prior 6 months. Participants wore blinded CGMs (Dexcom G6) during a 20‐day run‐in phase, with treatment based on fingerstick glucose values, followed by a 16‐week intervention phase and then a randomized 12‐week extension phase with treatment based on CGM values. The primary outcome was change in HbA1c. Secondary outcomes were CGM metrics. Safety endpoints were the number of severe hypoglycaemic (SH) and diabetic ketoacidosis (DKA) events.

Results

Of the 77 adults enrolled, 63 completed the study. Those enrolled had mean (SD) baseline HbA1c of 9.8% (1.9%), 36% had T1D, and 44% were ≥65 years old. Mean HbA1c decreased by 1.3, 1.0 and 1.0 percentage points for participants with T1D, T2D or age ≥65, respectively ( p < .001 for each). CGM‐based metrics including time in range also improved significantly. SH events decreased from the run‐in period (67.3 per 100 person‐years) to the intervention period (17.0 per 100 person‐years). Three DKA events unrelated to CGM use occurred during the total intervention period.

Conclusions

Non‐adjunctive use of the Dexcom G6 CGM system improved glycaemic control and was safe for adults using IIT.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic KetoacidosisAdultAgedHumansBlood GlucoseBlood Glucose Self-MonitoringGlycated HemoglobinHypoglycemic AgentsInsulinInsulin, Regular, HumanProspective Studies

Author keywords

blood glucose self-monitoringglycaemic controlglycated haemoglobin

Substances

Blood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinInsulin, Regular, Human

Authors and institutions

  • Dexcom, Inc., San Diego, California, USA.
  • Jaeb Center for Health Research, Tampa, Florida, USA.

ORCID profiles: Sarah B Andrade

Cite

APA

Chao, C., Andrade, S. B., Bergford, S., Calhoun, P., Welsh, J. B., Walker, T. C., & ANSHIN Study Group (2023). Assessing non‐adjunctive CGM safety at home and in new markets (ANSHIN). Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.414

Vancouver

Chao C, Andrade SB, Bergford S, Calhoun P, Welsh JB, Walker TC, et al. Assessing non‐adjunctive CGM safety at home and in new markets (ANSHIN). Endocrinology, Diabetes & Metabolism. 2023. doi:10.1002/edm2.414

BibTeX
@article{Chao2023,
  author = {Chao, Christy and Andrade, Sarah B and Bergford, Simon and Calhoun, Peter and Welsh, John B and Walker, Tomas C and ANSHIN Study Group, ANSHIN Study Group},
  title = {Assessing non‐adjunctive CGM safety at home and in new markets (ANSHIN)},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2023},
  doi = {10.1002/edm2.414}
}
Start for free →